Sickle cell drug safety trial ends early
NCT ID NCT05632354
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the long-term safety of the drug osivelotor in people with sickle cell disease who had already taken it in an earlier trial. The goal was to track side effects and blood changes over time. However, the study was terminated early, so the full safety picture is not yet known.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Osivelotor (a drug to help red blood cells carry oxygen better)
What this could lead to
If successful, this could provide a long-term treatment option to reduce painful crises in sickle cell disease.
What could go wrong
The trial was terminated early, so long-term safety and effectiveness data are limited. It is still an experimental drug with unknown risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aminu kano Teaching Hospital
Kano, 700233, Nigeria
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Lagos University Teaching Hospital
Lagos, 100254, Nigeria
-
Mississippi Center for Advanced Medicine
Madison, Mississippi, 39110, United States
-
Our Lady of the Lake Hospital, Inc.
Baton Rouge, Louisiana, 70808, United States
-
University College Hospital Ibadan
Ibadan, Oyo/ibadan North, 200212, Nigeria
-
University Medical Center Inpatient Pharmacy
New Orleans, Louisiana, 70112, United States
-
University Medical Center New Orleans
New Orleans, Louisiana, 70112, United States
-
University of Texas Health Science Center
Houston, Texas, 77030, United States